AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00806637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vessel sealing system uvulopalatoplasty (VSSU)
Description: Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
Study NCT01715142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
Study NCT00806637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uvulopalatal flap (UPF)
Description: Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
Study NCT04287140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus fluid administration
Description: 1000 ml of 0.9% normal saline bolus over one hour
Study NCT02321267 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab, aflibercept, pegaptanib, verteporphin
Description: ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
Study NCT03170843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of plastic ring wound retractor
Description: the experimental arm will use the plastic ring wound retractor for wound protection.
Study NCT01296594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT01296594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
Study NCT02055456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Study NCT02530398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinobufacini Injection
Description: Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
Study NCT03668171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell transplantation or placebo infusion via peripheral vein
Description: 0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
Study NCT03668171 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: mesenchymal stem cell transplantation or placebo infusion via peripheral vein
Description: 0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
Study NCT05988034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Administered orally.
Study NCT05988034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered orally.
Study NCT05988034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for avacopan
Description: Administered orally.
Study NCT05988034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxacin
Description: Administered orally.
Study NCT05988034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for moxifloxacin
Description: Administered orally.
Study NCT03330964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: Electroacupuncture was administrated immediately after completion of oxaliplatin infusion,once a day for 3 days,30 minutes each time.
Study NCT03995225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartband automatic smoking detection combined with brief mindfulness interventions
Description: Smartband/smartphone based automatic smoking monitoring, notification and real-time brief mindfulness interventions and learn to work mindfully with cravings and triggers rather than smoke using RAIN prior to smoking episodes.This is a 3 step intervention.
Study NCT02923193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Lithoplasty® Peripheral Lithoplasty System
Description: The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
Study NCT01126866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensified chemotherapy (FOLFOXIRI/Bevacizumab)
Description: intensified chemotherapy (FOLFOXIRI/Bevacizumab)
Study NCT02452554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02452554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lorvotuzumab Mertansine
Description: Given IV
Study NCT02452554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00744406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
Study NCT00744406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Description: All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
Study NCT00744406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (sertraline ,paroxetineor or venlafaxine)
Description: Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
Study NCT00448812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty with the Alair System
Description: Treatment of airways with the Alair System (Bronchial Thermoplasty) in the PREDECESSOR STUDY (NCT00214526).
Study NCT01819844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop blood glucose control
Description: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose > 2 u/kg).
Study NCT00771979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
Study NCT00771979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
Study NCT03071679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omignan 1%, 2.5%
Study NCT03071679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod 15mg
Study NCT03071679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan 1% and Imiquimod
Description: Omiganan 1% and Imiquimod
Study NCT03071679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan 2.5% and Imiquimod
Description: Omiganan 2.5% and Imiquimod
Study NCT03071679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT02425202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Post-operative continuous infusion until 0600 the next day
Study NCT02425202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: Post-operative continuous infusion until 0600 the next day
Study NCT02269254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Persona PS Knee Prosthesis by Zimmer
Description: Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
Study NCT02269254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen PS Knee Prosthesis by Zimmer
Description: Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
Study NCT01055080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk formula
Description: Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
Study NCT01055080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow's milk formula
Description: Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
Study NCT01551706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ENI Patented Whole Grape Extract
Description: ENI Patented Whole Grape Extract
Study NCT01551706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02624622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine application to cord by mother
Study NCT02624622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine application by CHW
Study NCT02184910 — intervention group
Intervention type: DRUG
Intervention: pepsinogen and gastrin
Study NCT04148898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Treatment of LM With osimertinb
Study NCT04148898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment of LM With osimertinb combined with bevacizumab
Study NCT03748121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama assisted trauma-focused Cognitive Behavioral Therapy (TF-CBT)
Description: The pranayama intervention is placed directly at the begin of the respective TF-CBT unit and will be repeated for 10 subsequent TF-CBT units. Pranayama contains the performance of Kapalabhati, Ujjayi, and/or Nadi Shodhana (for overall 1 minute) as well as following Kumbhaka (intentional respiratory reflex inhibition). Pranayama will be repeated 3 times before each TF-CBT unit.
Study NCT03748121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
Description: Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
Study NCT04938414 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar puncture
Description: Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test
Study NCT03056365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Nurse (AN)
Description: Protocoled AN-based management of detox
Study NCT03056365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Practitioner (GP)
Description: 'As usual' medical management of detox
Study NCT00392496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT02143167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-fampridine
Description: One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks.
Study NCT02143167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03201393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone and acetaminophen combination
Description: Twice a day
Study NCT03201393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day
Study NCT00221039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen+ECP
Description: UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
Study NCT02169388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Microbial composition using probiotic
Study NCT02169388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo（for probiotic）
Description: microbiota modulation using placebo
Study NCT01123772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-8875
Description: eye drops for 14 days in one eye
Study NCT01123772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Matched placebo
Study NCT02260349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green infusion
Description: intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
Study NCT00805519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine and chondroitin sulfate
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
Study NCT00805519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine and chondroitin sulfate plus Prednisolone
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
Study NCT00805519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine and Chondroitin sulfate plus Chloroquine
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
Study NCT00805519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
Study NCT00912106 — intervention group
Intervention type: OTHER
Intervention: Synovial fluid composition and lubrication analysis
Description: Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
Study NCT01790152 — intervention group
Intervention type: OTHER
Intervention: Assessment of Therapy Complications
Description: Ancillary studies
Study NCT01790152 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01790152 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01790152 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00865579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Description: The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning.
Study NCT01162122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)
Description: one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
Study NCT01162122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted trivalent subunit influenza vaccine (TIV)
Description: one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
Study NCT03597139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin Ophthalmic Solution
Description: Investigational Drug
Study NCT03597139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis®
Description: Comparator
Study NCT00357890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Description: CSII initiated within 1 month of diagnosis
Study NCT00357890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily injections using insulin glargine + rapid acting analog
Description: MDI as control
Study NCT05211141 — intervention group
Intervention type: DEVICE
Intervention: HLS KneeTec Deep Dish
Description: total knee arthroplasty with HLS KneeTec Deep Dish prosthesis
Study NCT02923193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medtronic IN.PACT (DCB)
Description: The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
Study NCT00076258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSRI + LD
Description: Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
Study NCT02923193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic IN.PACT (DCB)
Description: The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
Study NCT03293069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
Study NCT03293069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: the placebo twice daily morning and evening.
Study NCT03128528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10mg
Description: Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor.